Un Jung Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Un Jung Lee has a total of 165 co-authors. Here are the top co-authors by number of shared publications:
- Ayana K. April-Sanders
Department of Biostatistics & Epidemiology, Rutgers School of Public Health, Piscataway, USA
2 shared publications - James J. Chen
Department of Biostatistics,University of Arkansas for Medical Science, Little Rock, AR 72205, USA
2 shared publications - Priscilla Duran Luciano
Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York, USA
2 shared publications - Samuel Tanner
Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA
2 shared publications Akwi Asombang
1 shared publication- Aldo L. Schenone
Division of Cardiology, Montefiore Health System/Albert Einstein College of Medicine, Bronx, NY, USA
1 shared publication
Latest Publications
- Open Access
- 18 September 2026
- Published by Elsevier in The American Journal of Medicine
Plant-based diets and prevalent pre-heart failure in the Echocardiographic Study of Latinos (Echo-SOL)
- 18 September 2026
- Published by Elsevier in The American Journal of Medicine
Open AccessPlant-based diets and prevalent pre-heart failure in the Echocardiographic Study of Latinos (Echo-SOL)
- Open Access
- 24 November 2025
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (1)
High Burden of Pancreatic Surgery for Intraductal Papillary Mucinous Neoplasia With Low‐Grade Dysplasia and Benign Cysts: A Systematic Review and Meta‐Analysis
Background: Intraductal papillary mucinous neoplasms with low‐grade dysplasia (IPMNs w/LGD) and benign cysts, including serous cystadenomas (SCAs), are common pancreatic cystic lesions (PCLs) that are better managed conservatively. The burden of patients who undergo surgical resection for these cysts is unknown. Our study aims to estimate the global prevalence of surgical resections for IPMNs w/LGD and benign cysts, as well as the pre‐operative misclassification rate among all resected PCLs. Methods: We searched the literature through September 2023 to identify full‐text articles that reported the surgical histopathology of resected PCLs. A proportional meta‐analysis was performed using a random‐effects model, with prevalence estimates reported as pooled proportions. Subgroup analysis and meta‐regression were performed based on use of endoscopic ultrasound (EUS), years of enrollment, and geographic location. Results: Sixteen studies ( n = 5830) were identified. Among all surgically resected PCLs, 24% were IPMNs w/LGD (95% CI: 18%–32%), 16% were SCAs (95% CI 13%–19%), 4% were other benign cysts (95% CI: 3%–6%), and 24% were pre‐operatively misclassified (95% CI: 16%–34%). Of the resected IPMNs, 62% had LGD (95% CI: 51%–71%). An increasing use of pre‐operative EUS is associated with a lower prevalence of resected SCAs ( p < 0.05) but has not impacted the rate of resections for IPMNs w/LGD. The pre‐operative misclassification of PCLs has significantly decreased over time ( p < 0.01), although not significantly influenced by increasing EUS utilization or geographic location. Conclusion: One quarter of PCLs are pre‐operatively misclassified and ∼44% are surgically resected for benign cysts or IPMNs w/LGD. Implementation of advanced diagnostic tools might improve pre‐operative classification and reduce overtreatment of PCLs.
- 24 November 2025
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (1)
Open AccessHigh Burden of Pancreatic Surgery for Intraductal Papillary Mucinous Neoplasia With Low‐Grade Dysplasia and Benign Cysts: A Systematic Review and Meta‐Analysis
Background: Intraductal papillary mucinous neoplasms with low‐grade dysplasia (IPMNs w/LGD) and benign cysts, including serous cystadenomas (SCAs), are common pancreatic cystic lesions (PCLs) that are better managed conservatively. The burden of patients who undergo surgical resection for these cysts is unknown. Our study aims to estimate the global prevalence of surgical resections for IPMNs w/LGD and benign cysts, as well as the pre‐operative misclassification rate among all resected PCLs. Methods: We searched the literature through September 2023 to identify full‐text articles that reported the surgical histopathology of resected PCLs. A proportional meta‐analysis was performed using a random‐effects model, with prevalence estimates reported as pooled proportions. Subgroup analysis and meta‐regression were performed based on use of endoscopic ultrasound (EUS), years of enrollment, and geographic location. Results: Sixteen studies ( n = 5830) were identified. Among all surgically resected PCLs, 24% were IPMNs w/LGD (95% CI: 18%–32%), 16% were SCAs (95% CI 13%–19%), 4% were other benign cysts (95% CI: 3%–6%), and 24% were pre‐operatively misclassified (95% CI: 16%–34%). Of the resected IPMNs, 62% had LGD (95% CI: 51%–71%). An increasing use of pre‐operative EUS is associated with a lower prevalence of resected SCAs ( p < 0.05) but has not impacted the rate of resections for IPMNs w/LGD. The pre‐operative misclassification of PCLs has significantly decreased over time ( p < 0.01), although not significantly influenced by increasing EUS utilization or geographic location. Conclusion: One quarter of PCLs are pre‐operatively misclassified and ∼44% are surgically resected for benign cysts or IPMNs w/LGD. Implementation of advanced diagnostic tools might improve pre‐operative classification and reduce overtreatment of PCLs.
- Open Access
- 1 November 2025
- Published by Taylor & Francis in Clinical and Experimental Gastroenterology
- Vol. ume 18, 277-290
Chemopreventive Effects of Statins and Aspirin on Colorectal Cancer Among Patients with Inflammatory Bowel Disease: Evidence of a Synergistic Association from a Large Cohort
Background: Patients with Inflammatory Bowel Disease (IBD) are at an increased risk of developing colorectal cancer (CRC). While numerous studies have explored chemoprevention strategies in the general population, the specific roles of statins and aspirin in reducing CRC risk among IBD patients remain inconclusive. Aim: This study aims to evaluate the effect of statins on CRC risk and investigates whether combining statins and aspirin further reduces CRC risk in this high-risk population. Methods: We included 11,325 IBD patients from the Northwell Health Information Exchange (HIE) database (2008– 2023). Demographic and clinical variables were collected. The primary endpoint was CRC development, while the secondary endpoint was the occurrence of any cancer. Multivariable logistic regression assessed the association between cancer development and statin use, adjusted for confounders. Subgroup analyses evaluated the combined effect of statins and aspirin compared to non-users and aspirin-only users. Statistical significance was defined as a p-value < 0.05. Results: Among 11,325 patients (mean age 65.1± 20.4 years, 54.5% females, 68% white), 2,809 (24.8%) used statins. Logistic regression analysis revealed that statin use was associated with lower odds of CRC, although it did not reach statistical significance (OR: 0.647, p = 0.0564). It was, however, significantly associated with a reduced risk of any cancer (OR: 0.630, p< 0.0001). Furthermore, combining statins and aspirin significantly reduced the risk of CRC (OR: 0.163, p=0.0028) and any cancer (OR: 0.367, p< 0.0001) compared to non-users. When compared to aspirin-only users, the statin-aspirin combination was associated with significantly lower odds of CRC (OR: 0.235, p=0.0289) and any cancer (OR: 0.522, p=0.0087). Conclusion: Statins are associated with a reduced risk of any cancer and a potential reduction in CRC in patients with IBD. The combination of statin-aspirin demonstrates a significant and synergistic protective effect, supporting its potential role in chemoprevention strategies for this high-risk population.
- 1 November 2025
- Published by Taylor & Francis in Clinical and Experimental Gastroenterology
- Vol. ume 18, 277-290
Open AccessChemopreventive Effects of Statins and Aspirin on Colorectal Cancer Among Patients with Inflammatory Bowel Disease: Evidence of a Synergistic Association from a Large Cohort
Background: Patients with Inflammatory Bowel Disease (IBD) are at an increased risk of developing colorectal cancer (CRC). While numerous studies have explored chemoprevention strategies in the general population, the specific roles of statins and aspirin in reducing CRC risk among IBD patients remain inconclusive. Aim: This study aims to evaluate the effect of statins on CRC risk and investigates whether combining statins and aspirin further reduces CRC risk in this high-risk population. Methods: We included 11,325 IBD patients from the Northwell Health Information Exchange (HIE) database (2008– 2023). Demographic and clinical variables were collected. The primary endpoint was CRC development, while the secondary endpoint was the occurrence of any cancer. Multivariable logistic regression assessed the association between cancer development and statin use, adjusted for confounders. Subgroup analyses evaluated the combined effect of statins and aspirin compared to non-users and aspirin-only users. Statistical significance was defined as a p-value < 0.05. Results: Among 11,325 patients (mean age 65.1± 20.4 years, 54.5% females, 68% white), 2,809 (24.8%) used statins. Logistic regression analysis revealed that statin use was associated with lower odds of CRC, although it did not reach statistical significance (OR: 0.647, p = 0.0564). It was, however, significantly associated with a reduced risk of any cancer (OR: 0.630, p< 0.0001). Furthermore, combining statins and aspirin significantly reduced the risk of CRC (OR: 0.163, p=0.0028) and any cancer (OR: 0.367, p< 0.0001) compared to non-users. When compared to aspirin-only users, the statin-aspirin combination was associated with significantly lower odds of CRC (OR: 0.235, p=0.0289) and any cancer (OR: 0.522, p=0.0087). Conclusion: Statins are associated with a reduced risk of any cancer and a potential reduction in CRC in patients with IBD. The combination of statin-aspirin demonstrates a significant and synergistic protective effect, supporting its potential role in chemoprevention strategies for this high-risk population.
- Open Access
- 9 August 2025
- Published by Elsevier in Pancreatology
- Vol. 25 (6) , 860-867
Endoscopic ultrasound–guided celiac plexus block for painful chronic pancreatitis: A systematic review and meta-analysis
- 9 August 2025
- Published by Elsevier in Pancreatology
- Vol. 25 (6) , 860-867
Open AccessEndoscopic ultrasound–guided celiac plexus block for painful chronic pancreatitis: A systematic review and meta-analysis
- 13 August 2024
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 21 (12) , 1841-1850
Diagnostic Accuracy of Cone-Beam CT for Acute Intracranial Hemorrhage: A Systematic Review and Meta-Analysis
- 13 August 2024
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 21 (12) , 1841-1850
Diagnostic Accuracy of Cone-Beam CT for Acute Intracranial Hemorrhage: A Systematic Review and Meta-Analysis
- Open Access
- 8 January 2024
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 19 (1) , 71
Hypertension Prevalence among Hispanics/Latinos of Dominican Background: A Transnational Comparison of HCHS/SOL and ENPREFAR-HAS-17
Background: Hispanics/Latinos of Dominican background living in United States (US) have the highest hypertension prevalence compared with other Hispanic/Latino persons. Objective: To understand cardiovascular health among Dominicans, we evaluated hypertension prevalence and risk factors among Dominicans from the US and Dominican Republic (DR) using data from Hispanic Community Health Study/ Study of Latinos [HCHS/SOL] and the Prevalencia de Hipertension Arterial y Factores de Riesgo Cardiovasculares en la República Dominicana al 2017 (ENPREFAR-HAS 17) study. Methods: Hypertension was defined as blood pressure ≥140/90 mmHg, self-reported hypertension, or antihypertensive use. Exposures included sociodemographic/socioeconomic, clinical, and lifestyle/behavioral characteristics. Weighted generalized linear models were used to estimate associations between study characteristics and hypertension prevalence (PR = prevalence ratio), age-and-sex adjusted. HCHS/SOL (n = 1,473, US Dominicans; mean age 41 years, 60.4% female) was analyzed with survey procedures, while ENPREFAR-HAS 17 (n = 2,015 DR Dominicans; mean age 40 years, 50.3% female) was analyzed with statistical analyses for simple random sampling. Results: Hypertension prevalence was 30.5% and 26.9% for DR and US Dominicans, respectively. Hypertension control was low in both cohorts (36.0% DR, 35.0% US). Alcohol use among DR Dominicans was inversely associated with hypertension prevalence (PRDR = 0.8) with no association among US Dominicans. In both settings, diabetes (PRDR = 1.4; PRUS = 1.4) and obesity (PRDR = 1.8; PRUS = 2.0) were associated with greater hypertension prevalence in Hispanics/Latinos of Dominican background. Physical activity was lower among US Dominicans (PR = 0.80) but higher among DR Dominicans (PR = 1.16); all p < 0.05. Conclusions: Variations in social, lifestyle/behavioral, and clinical characteristics associated with hypertension among Dominicans in the US and DR were identified, suggesting that social context and cultural factors matter among immigrant populations.
- 8 January 2024
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 19 (1) , 71
Open AccessHypertension Prevalence among Hispanics/Latinos of Dominican Background: A Transnational Comparison of HCHS/SOL and ENPREFAR-HAS-17
Background: Hispanics/Latinos of Dominican background living in United States (US) have the highest hypertension prevalence compared with other Hispanic/Latino persons. Objective: To understand cardiovascular health among Dominicans, we evaluated hypertension prevalence and risk factors among Dominicans from the US and Dominican Republic (DR) using data from Hispanic Community Health Study/ Study of Latinos [HCHS/SOL] and the Prevalencia de Hipertension Arterial y Factores de Riesgo Cardiovasculares en la República Dominicana al 2017 (ENPREFAR-HAS 17) study. Methods: Hypertension was defined as blood pressure ≥140/90 mmHg, self-reported hypertension, or antihypertensive use. Exposures included sociodemographic/socioeconomic, clinical, and lifestyle/behavioral characteristics. Weighted generalized linear models were used to estimate associations between study characteristics and hypertension prevalence (PR = prevalence ratio), age-and-sex adjusted. HCHS/SOL (n = 1,473, US Dominicans; mean age 41 years, 60.4% female) was analyzed with survey procedures, while ENPREFAR-HAS 17 (n = 2,015 DR Dominicans; mean age 40 years, 50.3% female) was analyzed with statistical analyses for simple random sampling. Results: Hypertension prevalence was 30.5% and 26.9% for DR and US Dominicans, respectively. Hypertension control was low in both cohorts (36.0% DR, 35.0% US). Alcohol use among DR Dominicans was inversely associated with hypertension prevalence (PRDR = 0.8) with no association among US Dominicans. In both settings, diabetes (PRDR = 1.4; PRUS = 1.4) and obesity (PRDR = 1.8; PRUS = 2.0) were associated with greater hypertension prevalence in Hispanics/Latinos of Dominican background. Physical activity was lower among US Dominicans (PR = 0.80) but higher among DR Dominicans (PR = 1.16); all p < 0.05. Conclusions: Variations in social, lifestyle/behavioral, and clinical characteristics associated with hypertension among Dominicans in the US and DR were identified, suggesting that social context and cultural factors matter among immigrant populations.
- 30 December 2022
- Published by Springer Nature in The International Journal of Cardiovascular Imaging
- Vol. 39 (4) , 863-872
Influence of BMI on virtual coronary artery calcium scoring
Purpose Virtual non-contrast (VNC) coronary artery calcium scoring (CAC) may obviate the need for traditional non-contrast (TNC) CAC. There is no data on the influence of body mass index (BMI) on VNC reliability. We aimed to evaluate the influence of BMI on VNC CAC agreement with TNC. Materials and methods All patients who underwent sequential CAC and coronary CT angiography (CCTA) using spectral CT with TNC CAC > 0 between August 2020 and December 2021 were included. Agatston CAC scores were calculated manually by 2 blinded readers from VNC scans. A correction factor was calculated from the slope of the linear regression using the method of least squares and applied to the VNC scores. Bland-Altman plots and Cohen’s weighted Kappa were utilized. Results We included 174 patients (57.5% female). Mean BMI was 32.6 ± 7.02 kg/m2 [BMI < 30 (39.7%); BMI 30–40 (45.4%); and BMI > 40 kg/m2 (14.9%)]. Mean TNC CAC was 177.8 ± 316.86 and mean VNC CAC after applying the correction factor 149.34 ± 296.73. The TNC value strongly correlated with VNC (r = 0.94; p < 0.0001). As BMI increased there was a progressive reduction in signal-to-noise ratio, contrast-to-noise ratio and coronary enhancement (p < 0.05). The degree of agreement between VNC and TNC CAC decreased as BMI increased (agreement = 91.79 (weighted Kappa = 0.72), 91.14 (weighted Kappa = 0.58) and 88.46% (weighted Kappa = 0.48) (all P values < 0.001) for BMI < 30; 30–40 and > 40 kg/m2, respectively). Conclusion BMI has a significant influence on the accuracy of VNC CAC. VNC CAC shows substantial agreement in non-obese patients but performs poorly in BMI > 40 kg/m2. Summary statement This is the first study to evaluate the influence of body mass index (BMI) on virtual non-contrast (VNC) coronary artery calcium scoring (CAC) as compared to traditional non-contrast (TNC). We retrospectively evaluated 174 patients with TNC CAC and two blinded reviewers manually calculated the VNC CAC. All cases were included without specific selection for quality. The ratio between the two directly proportional values was determined using the slope from the linear regression through the method of least squares. This correction factor of 2.65 was applied to the calcium scores obtained from VNC images. We found that VNC CAC shows substantial risk-class agreement with TNC in non-obese patients (agreement = 91.79 and weighted Kappa = 0.72) but performs poorly in BMI > 40 kg/m2 (agreement: 88.46% and weighted Kappa = 0.48). These findings show the potential use of VNC CAC to avoid additional radiation in non-obese patients. However, further research on potential improvement strategies for VNC CAC in obese patients is needed.
- 30 December 2022
- Published by Springer Nature in The International Journal of Cardiovascular Imaging
- Vol. 39 (4) , 863-872
Influence of BMI on virtual coronary artery calcium scoring
Purpose Virtual non-contrast (VNC) coronary artery calcium scoring (CAC) may obviate the need for traditional non-contrast (TNC) CAC. There is no data on the influence of body mass index (BMI) on VNC reliability. We aimed to evaluate the influence of BMI on VNC CAC agreement with TNC. Materials and methods All patients who underwent sequential CAC and coronary CT angiography (CCTA) using spectral CT with TNC CAC > 0 between August 2020 and December 2021 were included. Agatston CAC scores were calculated manually by 2 blinded readers from VNC scans. A correction factor was calculated from the slope of the linear regression using the method of least squares and applied to the VNC scores. Bland-Altman plots and Cohen’s weighted Kappa were utilized. Results We included 174 patients (57.5% female). Mean BMI was 32.6 ± 7.02 kg/m2 [BMI < 30 (39.7%); BMI 30–40 (45.4%); and BMI > 40 kg/m2 (14.9%)]. Mean TNC CAC was 177.8 ± 316.86 and mean VNC CAC after applying the correction factor 149.34 ± 296.73. The TNC value strongly correlated with VNC (r = 0.94; p < 0.0001). As BMI increased there was a progressive reduction in signal-to-noise ratio, contrast-to-noise ratio and coronary enhancement (p < 0.05). The degree of agreement between VNC and TNC CAC decreased as BMI increased (agreement = 91.79 (weighted Kappa = 0.72), 91.14 (weighted Kappa = 0.58) and 88.46% (weighted Kappa = 0.48) (all P values < 0.001) for BMI < 30; 30–40 and > 40 kg/m2, respectively). Conclusion BMI has a significant influence on the accuracy of VNC CAC. VNC CAC shows substantial agreement in non-obese patients but performs poorly in BMI > 40 kg/m2. Summary statement This is the first study to evaluate the influence of body mass index (BMI) on virtual non-contrast (VNC) coronary artery calcium scoring (CAC) as compared to traditional non-contrast (TNC). We retrospectively evaluated 174 patients with TNC CAC and two blinded reviewers manually calculated the VNC CAC. All cases were included without specific selection for quality. The ratio between the two directly proportional values was determined using the slope from the linear regression through the method of least squares. This correction factor of 2.65 was applied to the calcium scores obtained from VNC images. We found that VNC CAC shows substantial risk-class agreement with TNC in non-obese patients (agreement = 91.79 and weighted Kappa = 0.72) but performs poorly in BMI > 40 kg/m2 (agreement: 88.46% and weighted Kappa = 0.48). These findings show the potential use of VNC CAC to avoid additional radiation in non-obese patients. However, further research on potential improvement strategies for VNC CAC in obese patients is needed.
- Open Access
- 9 May 2022
- Published by Wiley in Birth Defects Research
- Vol. 114 (16) , 1037-1055
Quantitative in vitro to in vivo extrapolation for developmental toxicity potency of valproic acid analogues
Background: The developmental toxicity potential (dTP) concentration from the devTOX quickPredict (devTOXqP) assay, a metabolomics‐based human induced pluripotent stem cell assay, predicts a chemical's developmental toxicity potency. Here, in vitro to in vivo extrapolation (IVIVE) approaches were applied to address whether the devTOXqP assay could quantitatively predict in vivo developmental toxicity lowest effect levels (LELs) for the prototypical teratogen valproic acid (VPA) and a group of structural analogues.Methods: VPA and a series of structural analogues were tested with the devTOXqP assay to determine dTP concentration and we estimated the equivalent administered doses (EADs) that would lead to plasma concentrations equivalent to the in vitro dTP concentrations. The EADs were compared to the LELs in rat developmental toxicity studies, human clinical doses, and EADs reported using other in vitro assays. To evaluate the impact of different pharmacokinetic (PK) models on IVIVE outcomes, we compared EADs predicted using various open‐source and commercially available PK and physiologically based PK (PBPK) models. To evaluate the effect of in vitro kinetics, an equilibrium distribution model was applied to translate dTP concentrations to free medium concentrations before subsequent IVIVE analyses.Results: The EAD estimates for the VPA analogues based on different PK/PBPK models were quantitatively similar to in vivo data from both rats and humans, where available, and the derived rank order of the chemicals was consistent with observed in vivo developmental toxicity. Different models were identified that provided accurate predictions for rat prenatal LELs and conservative estimates of human safe exposure. The impact of in vitro kinetics on EAD estimates is chemical‐dependent. EADs from this study were within range of predicted doses from other in vitro and model organism data.Conclusions: This study highlights the importance of pharmacokinetic considerations when using in vitro assays and demonstrates the utility of the devTOXqP human stem cell‐based platform to quantitatively assess a chemical's developmental toxicity potency.
- 9 May 2022
- Published by Wiley in Birth Defects Research
- Vol. 114 (16) , 1037-1055
Open AccessQuantitative in vitro to in vivo extrapolation for developmental toxicity potency of valproic acid analogues
Background: The developmental toxicity potential (dTP) concentration from the devTOX quickPredict (devTOXqP) assay, a metabolomics‐based human induced pluripotent stem cell assay, predicts a chemical's developmental toxicity potency. Here, in vitro to in vivo extrapolation (IVIVE) approaches were applied to address whether the devTOXqP assay could quantitatively predict in vivo developmental toxicity lowest effect levels (LELs) for the prototypical teratogen valproic acid (VPA) and a group of structural analogues.Methods: VPA and a series of structural analogues were tested with the devTOXqP assay to determine dTP concentration and we estimated the equivalent administered doses (EADs) that would lead to plasma concentrations equivalent to the in vitro dTP concentrations. The EADs were compared to the LELs in rat developmental toxicity studies, human clinical doses, and EADs reported using other in vitro assays. To evaluate the impact of different pharmacokinetic (PK) models on IVIVE outcomes, we compared EADs predicted using various open‐source and commercially available PK and physiologically based PK (PBPK) models. To evaluate the effect of in vitro kinetics, an equilibrium distribution model was applied to translate dTP concentrations to free medium concentrations before subsequent IVIVE analyses.Results: The EAD estimates for the VPA analogues based on different PK/PBPK models were quantitatively similar to in vivo data from both rats and humans, where available, and the derived rank order of the chemicals was consistent with observed in vivo developmental toxicity. Different models were identified that provided accurate predictions for rat prenatal LELs and conservative estimates of human safe exposure. The impact of in vitro kinetics on EAD estimates is chemical‐dependent. EADs from this study were within range of predicted doses from other in vitro and model organism data.Conclusions: This study highlights the importance of pharmacokinetic considerations when using in vitro assays and demonstrates the utility of the devTOXqP human stem cell‐based platform to quantitatively assess a chemical's developmental toxicity potency.
- 27 September 2020
- Published by Taylor & Francis in Journal of Toxicology and Environmental Health, Part A
- Vol. 83 (21-22) , 702-717
Performance of HepaRG and HepG2 cells in the high-throughput micronucleus assay for in vitro genotoxicity assessment
The micronucleus (MN) assay is a core test used to evaluate genotoxic potential of xenobiotics. The traditional in vitro MN assay is usually conducted in cells lacking metabolic competency or by supplementing cultures with an exogenous rat S9 metabolic system, which creates a significant assay limitation for detecting genotoxic metabolites. Our previous study demonstrated that compared to HepG2, HepaRG cells exhibited a significantly higher level of CYP450 enzyme activities and detected a greater portion of genotoxic carcinogens requiring metabolic activation using the Comet assay. The aim of this study was to assess the performance of HepaRG cells in the flow cytometry-based MN assay by testing 28 compounds with known genotoxic or carcinogenic modes of action (MoA). HepaRG cells exhibited higher sensitivity (83%) than HepG2 cells (67%) in detecting 12 indirect-acting genotoxicants or carcinogens. The HepaRG MN assay was 100% specific and 93% accurate in detecting genotoxic potential of the 28 compounds. Quantitative comparison of the MN concentration-response data using benchmark dose analysis showed that most of the tested compounds induced higher % MN in HepaRG than HepG2 cells. In addition, HepaRG cells were compatible with the Multiflow DNA damage assay, which predicts the genotoxic MoA of compounds tested. These results suggest that high-throughput flow cytometry-based MN assay may be adapted using HepaRG cells for genotoxicity assessment, and that HepaRG cells appear to be more sensitive than HepG2 cells in detecting genotoxicants or carcinogens that require metabolic activation.
- 27 September 2020
- Published by Taylor & Francis in Journal of Toxicology and Environmental Health, Part A
- Vol. 83 (21-22) , 702-717
Performance of HepaRG and HepG2 cells in the high-throughput micronucleus assay for in vitro genotoxicity assessment
The micronucleus (MN) assay is a core test used to evaluate genotoxic potential of xenobiotics. The traditional in vitro MN assay is usually conducted in cells lacking metabolic competency or by supplementing cultures with an exogenous rat S9 metabolic system, which creates a significant assay limitation for detecting genotoxic metabolites. Our previous study demonstrated that compared to HepG2, HepaRG cells exhibited a significantly higher level of CYP450 enzyme activities and detected a greater portion of genotoxic carcinogens requiring metabolic activation using the Comet assay. The aim of this study was to assess the performance of HepaRG cells in the flow cytometry-based MN assay by testing 28 compounds with known genotoxic or carcinogenic modes of action (MoA). HepaRG cells exhibited higher sensitivity (83%) than HepG2 cells (67%) in detecting 12 indirect-acting genotoxicants or carcinogens. The HepaRG MN assay was 100% specific and 93% accurate in detecting genotoxic potential of the 28 compounds. Quantitative comparison of the MN concentration-response data using benchmark dose analysis showed that most of the tested compounds induced higher % MN in HepaRG than HepG2 cells. In addition, HepaRG cells were compatible with the Multiflow DNA damage assay, which predicts the genotoxic MoA of compounds tested. These results suggest that high-throughput flow cytometry-based MN assay may be adapted using HepaRG cells for genotoxicity assessment, and that HepaRG cells appear to be more sensitive than HepG2 cells in detecting genotoxicants or carcinogens that require metabolic activation.